These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

127 related articles for article (PubMed ID: 752873)

  • 1. Controlled study for prolonged chemotherapy, immunotherapy, and chemotherapy plus immunotherapy as an adjuvant to surgery in malignant melanoma (Trial 6): preliminary report.
    Veronesi U; Beretta G
    Recent Results Cancer Res; 1978; 68():375-9. PubMed ID: 752873
    [No Abstract]   [Full Text] [Related]  

  • 2. Adjuvant therapy in malignant melanoma: a trial of immunotherapy. chemotherapy, and combined treatment.
    Kaufman SD; Cosimi AB; Wood WC; Carey RW
    Recent Results Cancer Res; 1978; 68():380-6. PubMed ID: 752874
    [No Abstract]   [Full Text] [Related]  

  • 3. Tumour regression and survival of patients with disseminated malignant melanoma treated with chemotherapy and specific active immunotherapy.
    Hedley DW; McElwain TJ; Currie GA
    Eur J Cancer (1965); 1977 Oct; 13(10):1169-73. PubMed ID: 923614
    [No Abstract]   [Full Text] [Related]  

  • 4. Value of adjuvant therapy with bacille Calmette Guerin (BCG) or dimethl triazeno imidazole carboximide (DTIC) in the control of minimal residual disease in stage II melanoma.
    Peter HH; Deutschmann KE; Deinhardt J; Deicher H
    Recent Results Cancer Res; 1978; 68():367-74. PubMed ID: 752872
    [No Abstract]   [Full Text] [Related]  

  • 5. Letter: Chemoimmunotherapy of malignant melanoma.
    N Engl J Med; 1975 Jan; 292(3):159-60. PubMed ID: 1196343
    [No Abstract]   [Full Text] [Related]  

  • 6. Clinical trial of combination chemotherapy and specific active immunotherapy in disseminated melanoma.
    Newlands ES; Oon CJ; Roberts JT; Elliott P; Mould RF; Topham C; Madden FJ; Newton KA; Westbury G
    Br J Cancer; 1976 Aug; 34(2):174-9. PubMed ID: 962994
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Bacillus Calmette-Guérin immunotherapy in combination with DTIC (NSC-45388) for the treatment of malignant melanoma.
    Gutterman JU; Mavligit GM; Reed R; Burgess MA; Gottlieb J; Hersh EM
    Cancer Treat Rep; 1976 Feb; 60(2):177-82. PubMed ID: 769970
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Randomized trial of adjuvant therapy for "high risk" primary malignant melanoma.
    Wood WC; Cosimi AB; Carey RW; Kaufman SD
    Surgery; 1978 Jun; 83(6):677-81. PubMed ID: 644461
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Adjuvant chemotherapy and immunotherapy in high risk patients with melanoma.
    El-Domeiri AA; Das Gupta TK; Trippon M; Simo C; Sabet TY; Crispen R
    Surg Gynecol Obstet; 1978 Feb; 146(2):230-2. PubMed ID: 622668
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized trial of adjuvant chemotherapy and immunotherapy in Stage I and Stage II cutaneous melanoma. An interim report.
    Sterchi JM; Wells HB; Case LD; Spurr CL; White DR; Richards F; Muss HB; Jackson DV; Stuart JJ; Cooper MR
    Cancer; 1985 Feb; 55(4):707-12. PubMed ID: 3967167
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Adjuvant immunotherapy of malignant melanoma.
    Aranha GV; McKhann CF; Grage TB; Gunnarsson A; Simmons RL
    Cancer; 1979 Apr; 43(4):1297-303. PubMed ID: 445331
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A randomized trial of adjuvant chemotherapy and immunotherapy in cutaneous melanoma.
    Veronesi U; Adamus J; Aubert C; Bajetta E; Beretta G; Bonadonna G; Bufalino R; Cascinelli N; Cocconi G; Durand J; De Marsillac J; Ikonopisov RL; Kiss B; Lejeune F; MacKie R; Madej G; Mulder H; Mechl Z; Milton GW; Morabito A; Peter H; Priario J; Paul E; Rumke P; Sertoli R; Tomin R
    N Engl J Med; 1982 Oct; 307(15):913-6. PubMed ID: 7050717
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Chemoimmunotherapy for disseminated malignant melanoma: a prospective randomized study.
    Ramseur WL; Richards F; Muss HB; Rhyne L; Cooper MR; White DR; Stuart JJ; Spurr CL
    Cancer Treat Rep; 1978 Jul; 62(7):1085-7. PubMed ID: 356970
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The survival of patients with malignant melanoma receiving BCG with or without chemotherapy.
    Green MD; MacKay IR; Buckley JC; Coates AS
    Aust N Z J Surg; 1979 Jun; 49(3):335-9. PubMed ID: 289374
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effect of chemotherapy and immunotherapy on tumor-specific immunity in melanoma.
    Mitchell MS; Mokyr MB; Davis JM
    J Clin Invest; 1977 Jun; 59(6):1017-26. PubMed ID: 863999
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Current results with surgery and adjuvant chemotherapy in malignant melanoma].
    Mechl Z; Kopecný J
    Arch Geschwulstforsch; 1986; 56(5):367-71. PubMed ID: 2429631
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Editorial: Treatment of malignant melanoma.
    Lancet; 1974 Nov; 2(7889):1119-20. PubMed ID: 4139412
    [No Abstract]   [Full Text] [Related]  

  • 18. Mature results of a phase III randomized trial of bacillus Calmette-Guerin (BCG) versus observation and BCG plus dacarbazine versus BCG in the adjuvant therapy of American Joint Committee on Cancer Stage I-III melanoma (E1673): a trial of the Eastern Oncology Group.
    Agarwala SS; Neuberg D; Park Y; Kirkwood JM
    Cancer; 2004 Apr; 100(8):1692-8. PubMed ID: 15073858
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [DTIC in malignant melanoma: a perspective (author's transl)].
    Kokoschka EM
    Wien Klin Wochenschr; 1978 Dec; 90(24):870-4. PubMed ID: 369152
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Experience with adjuvant chemoimmunotherapy with DTIC and BCG in malignant melanoma (author's transl)].
    Pullmann H; Muth M
    Z Hautkr; 1982 Feb; 57(4):294-7. PubMed ID: 7080583
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.